Anthony J. Kearsley

Anthony J. Kearsley

Auto-generated profile, based on publicly available information

Anthony J. Kearsley

National Institute of Standards and Technology

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Chromatography A
Verified
Journal Article
Closed access
CQChen Qu
Chen Qu
BSbarry Schneider
barry Schneider
AKAnthony J. Kearsley
Anthony J. Kearsley
WKWalid Keyrouz
Walid Keyrouz
TAThomas C. Allison
Thomas C. Allison

13 August 2021 in Mathematical Medicine and Biology: A Journal of the IMA
Verified
Journal Article
Open access
PDF file
PPPaul N Patrone
Paul N Patrone
AKAnthony J Kearsley
Anthony J Kearsley
Formulating accurate and robust classification strategies is a key challenge of developing diagnostic and antibody tests. Methods that do not explicitly account for disease prevalence and uncertainty therein can lead to significant classification errors. We present a novel method that leverages optimal decision theory to address this problem. As a preliminary step, we develop an analysis that uses an assumed prevalence and conditional probability models of diagnostic measurement outcomes to define optimal (in the sense of minimizing rates of false positives and false negatives) classification domains. Critically, we demonstrate how this strategy can be generalized to a setting in which the prevalence is unknown by either (i) defining a third class of hold-out samples that require further testing or (ii) using an adaptive algorithm to estimate prevalence prior to defining classification domains. We also provide examples for a recently published SARS-CoV-2 serology test and discuss how measurement uncertainty (e.g. associated with instrumentation) can be incorporated into the analysis. We find that our new strategy decreases classification error by up to a decade relative to more traditional methods based on confidence intervals. Moreover, it establishes a theoretical foundation for generalizing techniques such as receiver operating characteristics by connecting them to the broader field of optimization.

4 February 2022 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
CQChen Qu
Chen Qu
AKAnthony J. Kearsley
Anthony J. Kearsley
BSbarry Schneider
barry Schneider
WKWalid Keyrouz
Walid Keyrouz
TAThomas C. Allison
Thomas C. Allison

Verified
Journal Article
Open access
PDF file
LTLinhua Tian
Linhua Tian
EEElzafir B. Elsheikh
Elzafir B. Elsheikh
PPPa Pa
Pa Pa
AKAnthony J. Kearsley
Anthony J. Kearsley
AGAdolfas Gaigalas
Adolfas Gaigalas
LWLili Wang
Lili Wang
Quantitative and robust serology assays are critical measurements underpinning global COVID-19 response to diagnostic, surveillance, and vaccine development. Here, we report a proof-of-concept approach for the development of quantitative, multiplexed flow cytometry-based serological and neutralization assays. The serology assays test the IgG and IgM against both the full-length spike antigens and the receptor binding domain (RBD) of the spike antigen. Benchmarking against an RBD-specific SARS-CoV IgG reference standard, the anti-SARS-CoV-2 RBD antibody titer was quantified in the range of 37.6 µg/mL to 31.0 ng/mL. The quantitative assays are highly specific with no correlative cross-reactivity with the spike proteins of MERS, SARS1, OC43 and HKU1 viruses. We further demonstrated good correlation between anti-RBD antibody titers and neutralizing antibody titers. The suite of serology and neutralization assays help to improve measurement confidence and are complementary and foundational for clinical and epidemiologic studies.